Similar articles for PMID: 21948301

Year	Number of Results
1985	1
1986	1
1993	1
2000	1
2001	3
2002	1
2003	3
2004	1
2005	3
2006	3
2007	6
2008	2
2009	4
2010	1
2011	5
2012	4
2013	3
2014	5
2015	5
2016	10
2017	12
2018	8
2019	4
2020	5
2021	1
2023	1
2024	0

1

Novel treatment concepts for graft-versus-host disease.

Wolf D, von Lilienfeld-Toal M, Wolf AM, Schleuning M, von Bergwelt-Baildon M, Held SA, Brossart P. Wolf D, et al. Blood. 2012 Jan 5;119(1):16-25. doi: 10.1182/blood-2011-08-339465. Epub 2011 Sep 26. Blood. 2012. PMID: 21948301 Free article. Review.

2

Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.

Talmadge JE. Talmadge JE. Int Immunopharmacol. 2003 Aug;3(8):1121-43. doi: 10.1016/S1567-5769(03)00014-6. Int Immunopharmacol. 2003. PMID: 12860168 Review.

3

The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature.

Munneke JM, Spruit MJ, Cornelissen AS, van Hoeven V, Voermans C, Hazenberg MD. Munneke JM, et al. Transplantation. 2016 Nov;100(11):2309-2314. doi: 10.1097/TP.0000000000001029. Transplantation. 2016. PMID: 26714122 Review.

4

Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.

Theurich S, Fischmann H, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Scheid C, Skoetz N, von Bergwelt-Baildon M. Theurich S, et al. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009159. doi: 10.1002/14651858.CD009159.pub2. Cochrane Database Syst Rev. 2012. PMID: 22972135 Updated. Review.

5

Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.

Kim SS. Kim SS. Ann Pharmacother. 2007 Sep;41(9):1436-44. doi: 10.1345/aph.1K179. Epub 2007 Aug 7. Ann Pharmacother. 2007. PMID: 17684033 Review.

6

Acute graft-vs-host disease: pathobiology and management.

Goker H, Haznedaroglu IC, Chao NJ. Goker H, et al. Exp Hematol. 2001 Mar;29(3):259-77. doi: 10.1016/s0301-472x(00)00677-9. Exp Hematol. 2001. PMID: 11274753 Free article. Review.

7

Graft-versus-host disease management.

Mistrik M, Bojtarova E, Sopko L, Masakova L, Roziakova L, Martinka J, Batorova A. Mistrik M, et al. Bratisl Lek Listy. 2016;117(7):388-96. doi: 10.4149/bll_2016_077. Bratisl Lek Listy. 2016. PMID: 27546540

8

Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

Petersen SL. Petersen SL. Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.

9

[Treatment of graft-versus-host disease].

Ozawa Y. Ozawa Y. Rinsho Ketsueki. 2020;61(9):1395-1401. doi: 10.11406/rinketsu.61.1395. Rinsho Ketsueki. 2020. PMID: 33162541 Japanese.

10

Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.

Ikegame K, Yoshihara S, Taniguchi Y, Kaida K, Inoue T, Okada M, Taniguchi K, Hasei H, Tamaki H, Fujioka T, Kato R, Soma T, Ogawa H. Ikegame K, et al. Exp Hematol. 2011 Aug;39(8):880-90. doi: 10.1016/j.exphem.2011.05.007. Epub 2011 May 27. Exp Hematol. 2011. PMID: 21689724 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

85 results

Results by year